The new coronavirus for The constino biohasic has shown good prospects in mid-term studies.

The experimental coronavirus vaccine for Consino biobiology has shown encouraging results in mid-term clinical studies, paving the way for the next phase of testing. According to a study published in the medical journal The Lancet, the vaccine has been shown to be safe and causes an immune response in the body.

But the authors stressed that no participants were exposed to the SARS-CoV-2 virus after vaccination, so the study could not determine whether candidates could effectively prevent infection.

The new coronavirus for The constino biohasic has shown good prospects in mid-term studies.

The findings cement Consino Bio’s lead in the vaccine race. The company became one of the fastest-growing companies in May, the first to publish comprehensive scientific research on early human trials of vaccines, a crucial step because it allows researchers to assess the potential of drugs.

The experimental vaccine for Considine completes the second of three human tests that must be conducted before the drug is introduced. The new crown vaccine, developed jointly by AstraZeneca and Oxford University, also showed encouraging results in the first phase of trials, indicating progress in research and development.